Characterizing and predicting carcinogenicity and mode of action using conventional and toxicogenomics methods

Mutation Research - Reviews in Mutation Research

Volumn 705, Issue 3, 2010, Pages 184-200

  Waters, Michael D ^a   Jackson, Marcus ^a   Lea, Isabel ^a  

^a INTEGRATED LABORATORY SYSTEMS   (United States)

Author keywords

Predictive toxicogenomics, Carcinogenicity, Genotoxic, Nongenotoxic

Indexed keywords

1 NITROPROPANE; 2 NITRO 1,4 PHENYLENEDIAMINE; 2 NITROFLUORENE; 2 NITROPROPANE; 2,4 DIAMINOTOLUENE; 2,6 DIAMINOTOLUENE; 4 NITRO 1,2 PHENYLENEDIAMINE; AFLATOXIN B1; ANILINE; BUTYLCRESOL; CARCINOGEN; CISPLATIN; CYCLOPHOSPHAMIDE; CYPROTERONE ACETATE; DIBENZ[A,H]ANTHRACENE; DIELDRIN; DIETHYLSTILBESTROL; DIMETHYLNITROSAMINE; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; FLUORANTHENE; FUROSEMIDE; ISONIAZID; METHAPYRILENE; MITOMYCIN C; MONOCROTALINE; N (2 FLUORENYL)ACETAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOBARBITAL; PIPERONYL BUTOXIDE; UNINDEXED DRUG;

ANEUPLOIDY; CARCINOGENICITY; CHROMOSOME ABERRATION; CYTOTOXICITY; DNA DAMAGE; DNA MODIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DAMAGE; GENOTOXICITY; HUMAN; LIVER TOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RODENT; TOXICOGENETICS;

ANIMALS; BIOLOGICAL ASSAY; CARCINOGENICITY TESTS; CARCINOGENS; DNA DAMAGE; DRUG EVALUATION, PRECLINICAL; FEMALE; GENOMICS; HUMANS; MALE; MICE; RATS; TOXICOGENETICS; TOXICOLOGY;

RODENTIA;

EID: 78649318364     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrrev.2010.04.005     Document Type: Review

References (100)

1. Ellinger-Ziegelbauer H., Aubrecht J., Kleinjans J.C., Ahr H.J. Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity. Toxicol. Lett. 2009, 186:36-44.
2. Ellinger-Ziegelbauer H., Stuart B., Wahle B., Bomann W., Ahr H.J. Comparison of the expression profiles induced by genotoxic and nongenotoxic carcinogens in rat liver. Mutat. Res. 2005, 575:61-84.
3. Fielden M.R., Brennan R., Gollub J. A gene expression biomarker provides early prediction and mechanistic assessment of hepatic tumor induction by nongenotoxic chemicals. Toxicol. Sci. 2007, 99:90-100.
4. Fielden M.R., Nie A., McMillian M., Elangbam C.S., Trela B.A., Yang Y., Dunn R.T., Dragan Y., Fransson-Stehen R., Bogdanffy M., Adams S.P., Foster W.R., Chen S.J., Rossi P., Kasper P., Jacobson-Kram D., Tatsuoka K.S., Wier P.J., Gollub J., Halbert D.N., Roter A., Young J.K., Sina J.F., Marlowe J., Martus H.J., Aubrecht J., Olaharski A.J., Roome N., Nioi P., Pardo I., Snyder R., Perry R., Lord P., Mattes W., Car B.D. Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the rat. Toxicol. Sci. 2008, 103:28-34.
5. Nakayama K., Kawano Y., Kawakami Y., Moriwaki N., Sekijima M., Otsuka M., Yakabe Y., Miyaura H., Saito K., Sumida K., Shirai T. Differences in gene expression profiles in the liver between carcinogenic and non-carcinogenic isomers of compounds given to rats in a 28-day repeat-dose toxicity study. Toxicol. Appl. Pharmacol. 2006, 217:299-307.
6. Nie A.Y., McMillian M., Parker J.B., Leone A., Bryant S., Yieh L., Bittner A., Nelson J., Carmen A., Wan J., Lord P.G. Predictive toxicogenomics approaches reveal underlying molecular mechanisms of nongenotoxic carcinogenicity. Mol. Carcinog. 2006, 45:914-933.
7. Thomas R.S., Pluta L., Yang L., Halsey T.A. Application of genomic biomarkers to predict increased lung tumor incidence in 2-year rodent cancer bioassays. Toxicol. Sci. 2007, 97:55-64.
8. Tsujimura K., Asamoto M., Suzuki S., Hokaiwado N., Ogawa K., Shirai T. Prediction of carcinogenic potential by a toxicogenomic approach using rat hepatoma cells. Cancer Sci. 2006, 97:1002-1010.
9. Ellinger-Ziegelbauer H., Gmuender H., Bandenburg A., Ahr H.J. Prediction of a carcinogenic potential of rat hepatocarcinogens using toxicogenomics analysis of short-term in vivo studies. Mutat. Res. 2008, 637:23-39.
10. Van Delft J.H., Van Agen E., Van Breda S.G., Herwijnen M.H., Staal Y.C., Kleinjans J.C. Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling. Carcinogenesis 2004, 25:1265-1276.
11. van Delft J.H., van Agen E., van Breda S.G., Herwijnen M.H., Staal Y.C., Kleinjans J.C. Comparison of supervised clustering methods to discriminate genotoxic from non-genotoxic carcinogens by gene expression profiling. Mutat. Res. 2005, 575:17-33.
12. Eastmond D.A., Hartwig A., Anderson D., Anwar W.A., Cimino M.C., Dobrev I., Douglas G.R., Nohmi T., Phillips D.H., Vickers C. Mutagenicity testing for chemical risk assessment: update of the WHO/IPCS harmonized scheme. Mutagenesis 2009, 24:341-349.
13. Bucher J.R., Portier C. Human carcinogenic risk evaluation. Part V: the national toxicology program vision for assessing the human carcinogenic hazard of chemicals. Toxicol. Sci. 2004, 82:363-366.
14. Gold L.S., Manley N.B., Slone T.H., Rohrbach L., Garfinkel G.B. Supplement to the Carcinogenic Potency Database (CPDB): results of animal bioassays published in the general literature through 1997 and by the National Toxicology Program in 1997-1998. Toxicol. Sci. 2005, 85:747-808.
15. L. Gold, "Summary by Chemical of Carcinogenicity Results in the Carcinogen Potency Data Base (CPDB) from Technical Reports of the NCI/NTP" (2009).
16. Fung V.A., Barrett J.C., Huff J. The carcinogenesis bioassay in perspective: application in identifying human cancer hazards. Environ. Health Perspect. 1995, 103:680-683.
17. Waters M.D., Auletta A. The GENE-TOX program: genetic activity evaluation. J. Chem. Inf. Comput. Sci. 1981, 21:35-38.
18. Waters M.D., Stack H.F., Jackson M.A. Genetic toxicology data in the evaluation of potential human environmental carcinogens. Mutat. Res. 1999, 437:21-49.
19. Kirkland D., Speit G. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens III. Appropriate follow-up testing in vivo. Mutat. Res. 2008, 654:114-132.
20. Kirkland D., Aardema M., Henderson L., Muller L. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens I. Sensitivity, specificity and relative predictivity. Mutat. Res. 2005, 584:1-256.
21. Kirkland D., Aardema M., Muller L., Makoto H. Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens II. Further analysis of mammalian cell results, relative predictivity and tumour profiles. Mutat. Res. 2006, 608:29-42.
22. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. USA 1975, 72:5135-5139.
23. McCann J., Ames B.N. Discussion paper: the detection of mutagenic metabolites of carcinogens in urine with the Salmonella/microsome test. Ann. N Y Acad. Sci. 1975, 269:21-25.
24. Claxton L.D., Stead A.G., Walsh D. An analysis by chemical class of Salmonella mutagenicity tests as predictors of animal carcinogenicity. Mutat. Res. 1988, 205:197-225.
25. Jackson M.A., Stack H.F., Waters M.D. The genetic toxicology of putative nongenotoxic carcinogens. Mutat. Res. 1993, 296:241-277.
26. Butterworth B.E. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat. Res. 1990, 239:117-132.
27. Ames B.N., Durston W.E., Yamasaki E., Lee F.D. Carcinogens are mutagens: a simple test system combining liver homogenates for activation and bacteria for detection. Proc. Natl. Acad. Sci. USA 1973, 70:2281-2285.
28. Long M.E. Predicting carcinogenicity in humans: The need to supplement animal-based toxicology. AATEX 2007, 14:553-559.
29. LeBoeuf R.A., Kerckaert G.A., Aardema M.J., Gibson D.P., Brauninger R., Isfort R.J. The pH 6.7 Syrian hamster embryo cell transformation assay for assessing the carcinogenic potential of chemicals. Mutat. Res. 1996, 356:85-127.
30. Custer L., Gibson D.P., Aardema M.J., LeBoeuf R.A. A refined protocol for conducting the low pH 6.7 Syrian hamster embryo (SHE) cell transformation assay. Mutat. Res. 2000, 455:129-139.
31. Kerckaert G.A., Isfort R.J., Carr G.J., Aardema M.J., LeBoeuf R.A. A comprehensive protocol for conducting the Syrian hamster embryo cell transformation assay at pH 6.70. Mutat. Res. 1996, 356:65-84.
32. OECD detailed review paper on nongenotoxic carcinogens detection: the performance of in-vitro cell transformation assays, OECD Environment, Health and Safety Publications Series on Testing and Assessment, 2007, 164 p.
33. Kinoshita M., Miyata M. Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 2002, 36:433-438.
34. Snyder R.D., Green J.W. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 2001, 488:151-169.
35. Gold L.S., Slone T.H., Stern B.R., Bernstein L. Comparison of target organs of carcinogenicity for mutagenic and non-mutagenic chemicals. Mutat. Res. 1993, 286:75-100.
36. Aubrecht J., Caba E. Gene expression profile analysis: an emerging approach to investigate mechanisms of genotoxicity. Pharmacogenomics 2005, 6:419-428.
37. Amundson S.A., Fornace A.J. Gene expression profiles for monitoring radiation exposure. Radiat. Prot. Dosim. 2001, 97:11-16.
38. Amundson S.A., Do K.T., Fornace A.J. Induction of stress genes by low doses of gamma rays. Radiat. Res. 1999, 152:225-231.
39. Fornace A.J., Amundson S.A., Bittner M., Myers T.G., Meltzer P., Weinsten J.N., Trent J. The complexity of radiation stress responses: analysis by informatics and functional genomics approaches. Gene Expr. 1999, 7:387-400.
40. Amundson S.A., Bittner M., Fornace A.J. Functional genomics as a window on radiation stress signaling. Oncogene 2003, 22:5828-5833.
41. Snyder A.R., Morgan W.F. Gene expression profiling after irradiation: clues to understanding acute and persistent responses?. Cancer Metastasis Rev. 2004, 23:259-268.
42. Grombacher T., Eichhorn U., Kaina B. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene 1998, 17:845-851.
43. Kimura S.H., Nojima H. Cyclin G1 associates with MDM2 and regulates accumulation and degradation of p53 protein. Genes Cells 2002, 7:869-880.
44. Momand J., Wu H.H., Dasgupta G. MDM2 - master regulator of the p53 tumor suppressor protein. Gene 2000, 242:15-29.
45. Rouault J.P., Falette N., Guehenneux F., Guillot C., Rimokh R., Wang Q., Berthet C., Moyret-Lalle C., Savatier P., Pain B., Shaw P., Berger R., Samarut J., Magaud J.P., Ozturk M., Samarut C., Puisieux A. Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat. Genet. 1996, 14:482-486.
46. Kohn K.W. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol. Biol. Cell 1999, 10:2703-2734.
47. Ellinger-Ziegelbauer H., Stuart B., Wahle B., Bomann W., Ahr H.J. Characteristic expression profiles induced by genotoxic carcinogens in rat liver. Toxicol. Sci. 2004, 77:19-34.
48. Brazma A., Parkinson H., Sarkans U., Shojatalab M., Vilo J., Abeygunawardena N., Holloway E., Kapushesky M., Kemmeren P., Lara G.G., Oezcimen A., Rocca-Serra P., Sansone S.A. ArrayExpress - a public repository for microarray gene expression data at the EBI. Nucleic Acids Res. 2003, 31:68-71.
49. Akerman G.S., Rosenzweig B.A., Domon O.E., McGarrity L.J., Blankenship L.R., Tsai C.A., Culp S.J., MacGregor J.T., Sistare F.D., Chen J.J., Morris S.M. Gene expression profiles and genetic damage in benzo(a)pyrene diol epoxide-exposed TK6 cells. Mutat. Res. 2004, 549:43-64.
50. Amundson S.A., Do K.T., Vinikoor L., Koch-Paiz C.A., Bittner M.L., Trent J.M., Meltzer P., Fornace A.J. Stress-specific signatures: expression profiling of p53 wild-type and -null human cells. Oncogene 2005, 24:4572-4579.
51. Islaih M., Halstead B.W., Kadura I.A., Li B., Reid-Hubbard J.L., Flick L., Altizer J.L., Thom Deahl J., Monteith D.K., Newton R.K., Watson D.E. Relationships between genomic, cell cycle, and mutagenic responses of TK6 cells exposed to DNA damaging chemicals. Mutat. Res. 2005, 578:100-116.
52. Bishayee A., Roy S., Chatterjee M. Characterization of selective induction and alteration of xenobiotic biotransforming enzymes by vanadium during diethylnitrosamine-induced chemical rat liver carcinogenesis. Oncol. Res. 1999, 11:41-53.
53. Kuo W.H., Chiang W.L., Yang S.F., Yeh K.T., Yeh C.M., Hsieh Y.S., Chu S.C. The differential expression of cytosolic carbonic anhydrase in human hepatocellular carcinoma. Life Sci. 2003, 73:2211-2223.
54. Escher G., Nawrocki A., Staub T., Vishwanath B.S., Frey B.M., Reichen J., Frey F.J. Down-regulation of hepatic and renal 11 beta-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 1998, 114:175-184.
55. Lamberti A., Caraglia M., Longo O., Marra M., Abbruzzese A., Arcari P. The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis: review article. Amino Acids 2004, 26:443-448.
56. Thornton S., Anand N., Purcell D., Lee J. Not just for housekeeping: protein initiation and elongation factors in cell growth and tumorigenesis. J. Mol. Med. 2003, 81:536-548.
57. Joseph P., O'Kernick C.M., Othumpangat S., Lei Y.X., Yuan B.Z., Ong T.M. Expression profile of eukaryotic translation factors in human cancer tissues and cell lines. Mol. Carcinog. 2004, 40:171-179.
58. NCI Technical Report No.169, Bioassay of 2-nitro-p-phenylenediamine for Possible Carcinogenicity, National Cancer Institute, Bethesda, MD, 1979.
59. Fornace A.J., Alamo I., Hollander M.C. DNA damage-inducible transcripts in mammalian cells. Proc. Natl. Acad. Sci. USA 1988, 85:8800-8804.
60. Fornace A.J., Nebert D.W., Hollander M.C., Luethy J.D., Papathanasiou M., Fargnoli J., Holbrook N.J. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. Mol. Cell Biol. 1989, 9:4196-4203.
61. Amundson S.A., Bittner M., Meltzer P., Trent J., Fornace A.J. Physiological function as regulation of large transcriptional programs: the cellular response to genotoxic stress. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 2001, 129:703-710.
62. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
63. Heijne W.H, Stierum R.H., Slijper M., van Bladeren P.J., van Ommen B. Toxicogenomics of bromobenzene hepatotoxicity: a combined transcriptomics and proteomics approach. Biochem. Pharmacol. 2003, 65:857-875.
64. Teeter L.D., Estes M., Chan J.Y., Atassi H., Sell S., Becker F.F., Kuo M.T. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. Mol. Carcinog. 1993, 8:67-73.
65. Dinkova-Kostova A.T., Holtzclaw W.D., Kensler T.W. The role of Keap1 in cellular protective responses. Chem. Res. Toxicol. 2005, 18:1779-1791.
66. Yao R., Wang Y., Lubet R.A., You M. Differential gene expression in chemically induced mouse lung adenomas. Neoplasia 2003, 5:41-52.
67. Edgar R., Domrachev M., Lash A.E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002, 30:207-210.
68. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., Coller H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
69. Tukey R.H., Strassburg C.P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000, 40:581-616.
70. Strassburg C.P., Manns M.P., Tukey R.H. Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res. 1997, 57:2979-2985.
71. Kramer J.A., Curtiss S.W., Kolaja K.L., Alden C.L., Blomme E.A., Curtiss W.C., Davila J.C., Jackson C.J., Bunch R.T. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 2004, 17:463-470.
72. Ghosh S. Cholesteryl ester hydrolase in human monocyte/macrophage: cloning, sequencing, and expression of full-length cDNA. Physiol. Genomics 2000, 2:1-8.
73. Uphoff C.C., Drexler H.G. Biology of monocyte-specific esterase. Leuk. Lymphoma 2000, 39:257-270.
74. Munger J.S., Shi G.P., Mark E.A., Chin D.T., Gerard C., Chapman H.A. A serine esterase released by human alveolar macrophages is closely related to liver microsomal carboxylesterases. J. Biol. Chem. 1991, 266:18832-18838.
75. Arand M., Cronin A., Adamska M., Oesch F. Epoxide hydrolases: structure, function, mechanism, and assay. Methods Enzymol. 2005, 400:569-588.
76. Coller J.K., Fritz P., Zanger U.M., Siegle I., Eichelbaum M., Kroemer H.K., Murdter T.E. Distribution of microsomal epoxide hydrolase in humans: an immunohistochemical study in normal tissues, and benign and malignant tumours. Histochem. J. 2001, 33:329-336.
77. Hayes J.D., Pulford D.J. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995, 30:445-600.
78. Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem. Funct. 2004, 22:343-352.
79. Kwak M.K., Wakabayashi N., Kensler T.W. Chemoprevention through the Keap1-Nrf2 signaling pathway by phase 2 enzyme inducers. Mutat. Res. 2004, 555:133-148.
80. Breuhahn K., Longerich T., Schirmacher P. Dysregulation of growth factor signaling in human hepatocellular carcinoma. Oncogene 2006, 25:3787-3800.
81. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
82. Costello L.C., Franklin R.B. 'Why do tumour cells glycolyse?': from glycolysis through citrate to lipogenesis. Mol. Cell. Biochem. 2005, 280:1-8.
83. Mazurek S., Boschek C.B., Eigenbrodt E. The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy. J. Bioenerg. Biomembr. 1997, 29:315-330.
84. Hasegawa R., Ito N. Hepatocarcinogenesis in the Rat 1994, Raven Press, New York.
85. Datta S., Datta M.W. Sonic Hedgehog signaling in advanced prostate cancer. Cell. Mol. Life Sci. 2006, 63:435-448.
86. Srinivasan D.M., Kapoor M., Kojima F., Crofford L.J. Growth factor receptors: implications in tumor biology. Curr. Opin. Investig. Drugs 2005, 6:1246-1249.
87. Combes R.D. The use of structure-activity relationships and markers of cell toxicity to detect non-genotoxic carcinogens. Toxicol. In Vitro 2000, 14:387-399.
88. Kramer J.A., Curtiss S.W., Kolaja K.L., Alden C.L., Blomme E.A.G., Curtiss W.C., Davila J.C., Jackson C.J., Bunch R.T. Acute molecular markers of rodent hepatic carcinogenesis identified by transcription profiling. Chem. Res. Toxicol. 2004, 17:463-470.
89. Waters M., Stasiewicz S., Merrick B.A., Tomer K., Bushel P., Paules R., Stegman N., Nehls G., Yost K.J., Johnson C.H., Gustafson S.F., Xirasagar S., Xiao N., Huang C.C., Boyer P., Chan D.D., Pan Q., Gong H., Taylor J., Choi D., Rashid A., Ahmed A., Howle R., Selkirk J., Tennant R., Fostel J. CEBS - chemical effects in biological systems: a public data repository integrating study design and toxicity data with microarray and proteomics data. Nucleic Acids Res. 2008, 36:D892-900.
90. Wilson A.G., Thake D.C., Heydens W.E., Brewster D.W., Hotz K.J. Mode of action of thyroid tumor formation in the male Long-Evans rat administered high doses of alachlor. Fundam. Appl. Toxicol. 1996, 33:16-23.
91. Waalkes M.P., Liu J., Goyer R.A., Diwan B.A. Metallothionein-I/II double knockout mice are hypersensitive to lead-induced kidney carcinogenesis: role of inclusion body formation. Cancer Res. 2004, 64:7766-7772.
92. Oster S.K., Ho C.S., Soucie E.L., Penn L.Z. The myc oncogene: MarvelouslY complex. Adv. Cancer Res. 2002, 84:81-154.
93. Ganter B., Tugendreich S., Pearson C.I., Ayanoglu E., Baumhueter S., Bostian K.A., Brady L., Browne L.J., Calvin J.T., Day G.J., Breckenridge N., Dunlea S., Eynon B.P., Furness L.M., Ferng J., Fielden M.R., Fujimoto S.Y., Gong L., Hu C., Idury R., Judo M.S., Kolaja K.L., Lee M.D., McSorley C., Minor J.M., Nair R.V., Natsoulis G., Nguyen P., Nicholson S.M., Pham H., Roter A.H., Sun D., Tan S., Thode S., Tolley A.M., Vladimirova A., Yang J., Zhou Z., Jarnagin K. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action. J. Biotechnol. 2005, 119:219-244.
94. Steinmetz K.L., Tyson C.K., Meierhenry E.F., Spalding J.W., Mirsalis J.C. Examination of genotoxicity, toxicity and morphologic alterations in hepatocytes following in vivo or in vitro exposure to methapyrilene. Carcinogenesis 1988, 9:959-963.
95. Willhite C.C. Weight-of-evidence versus strength-of-evidence in toxicologic hazard identification: Di(2-ethylhexyl)phthalate (DEHP). Toxicology 2001, 160:219-226.
96. Thomas R.S., Bao W., Chu T.M., Bessarabova M., Nikolskaya T., Nikolsky Y., Andersen M.E., Wolfinger R.D. Use of short-term transcriptional profiles to assess the long-term cancer-related safety of environmental and industrial chemicals. Toxicol. Sci. 2009, 112:311-321.
97. Alexander D.J., Libretto S.E., Chevalier H.J., Imamura T., Pappritz G., Wilson J. HFA-134a (1,1,1,2-tetrafluoroethane); lack of oncogenicity in rodents after inhalation. Hum. Exp. Toxicol. 1995, 14:706-714.
98. Andersen M.E., Mills J.J., Jirtle R.L., Greenlee W.F. Negative selection in hepatic tumor promotion in relation to cancer risk assessment. Toxicology 1995, 102:223-237.
99. Yauk C.L., Berndt M.L. Review of the literature examining the correlation among DNA microarray technologies. Environ. Mol. Mutagen. 2007, 48:380-394.
100. OECD Detailed Review Paper on Cell Transformation, Assays for Detection of Chemical Carcinogens, 2006, 170 p.